Breakthrough drug can cut chances of lung cancer returning by a third when used alongside chemotherapy and surgery...so why have NHS chiefs rejected it?

Durvalumab has been shown in trials to be effective at curing patients with the most common form of lung cancer when combined in the early stages of the disease alongside chemotherapy.

  Health   Sep 1, 2024   0   8  Add to Reading List
Breakthrough drug can cut chances of lung cancer returning by a third when used alongside chemotherapy and surgery...so why have NHS chiefs rejected it?

INCREASE YOUR SALES WITH NGN1,000 TODAY!

Advertise on doacWeb

WhatsApp: 09031633831

To reach more people from NGN1,000 now!

INCREASE YOUR SALES WITH NGN1,000 TODAY!

Advertise on doacWeb

WhatsApp: 09031633831

To reach more people from NGN1,000 now!

INCREASE YOUR SALES WITH NGN1,000 TODAY!

Advertise on doacWeb

WhatsApp: 09031633831

To reach more people from NGN1,000 now!

Durvalumab has been shown in trials to be effective at curing patients with the most common form of lung cancer when combined in the early stages of the disease alongside chemotherapy.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow